Jubilant Pharmova [JUBLPHARMA] vs Concord Biotech [CONCORDBIO] Detailed Stock Comparison

Jubilant Pharmova

NSE

Concord Biotech

NSE

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Jubilant Pharmova wins in 10 metrics, Concord Biotech wins in 10 metrics, with 0 ties. Both stocks appear equally matched on key metrics.

View Metrics Details

Vital Metrics Comparison

Metric	Jubilant Pharmova	Concord Biotech	Better
P/E Ratio (TTM)	36.96	49.11	Jubilant Pharmova
Price-to-Book Ratio	2.71	9.63	Jubilant Pharmova
Debt-to-Equity Ratio	43.78	0.16	Concord Biotech
PEG Ratio	-0.47	-1.88	Concord Biotech
EV/EBITDA	15.13	35.54	Jubilant Pharmova
Profit Margin (TTM)	6.22%	29.97%	Concord Biotech
Operating Margin (TTM)	10.08%	21.38%	Concord Biotech
EBITDA Margin (TTM)	10.08%	21.38%	Concord Biotech
Return on Equity	13.45%	20.50%	Concord Biotech
Return on Assets (TTM)	6.58%	18.27%	Concord Biotech
Free Cash Flow (TTM)	$-435.00M	$1.33B	Concord Biotech
Dividend Yield	0.85%	0.44%	Jubilant Pharmova
1-Year Return	12.48%	-9.71%	Jubilant Pharmova
Price-to-Sales Ratio (TTM)	2.29	14.69	Jubilant Pharmova
Enterprise Value	$185.97B	$171.48B	Jubilant Pharmova
EV/Revenue Ratio	2.51	14.43	Jubilant Pharmova
Gross Profit Margin (TTM)	67.10%	77.89%	Concord Biotech
Revenue per Share (TTM)	$467	$114	Jubilant Pharmova
Earnings per Share (Diluted)	$28.96	$33.98	Concord Biotech
Beta (Stock Volatility)	0.69	0.95	Jubilant Pharmova

Performance

Key Stats

Valuation

Financials

Short Interest

Dividends

Jubilant Pharmova vs Concord Biotech Stock Performance Analysis

Loading Price Chart...

Performance Comparison

Short-term Returns

Stock	1D	1W	1M	3M	6M	YTD
Jubilant Pharmova	0.53%	4.62%	-4.35%	-6.29%	19.48%	-0.88%
Concord Biotech	-0.66%	-1.43%	-2.58%	-10.43%	-5.14%	-22.85%

Long-term Returns

Stock	1Y	3Y	5Y	10Y	15Y	20Y
Jubilant Pharmova	12.48%	228.80%	93.16%	243.02%	210.39%	2,686.05%
Concord Biotech	-9.71%	75.83%	75.83%	75.83%	75.83%	75.83%

Performance & Financial Health Analysis: Jubilant Pharmova vs Concord Biotech

Metric	JUBLPHARMA	CONCORDBIO
Market Information
Market Cap i	₹169.87B	₹173.68B
Market Cap Category	Mid cap	Mid cap
10 Day Avg. Volume i	130,425	114,810
90 Day Avg. Volume i	277,029	117,481
Last Close	₹1,070.40	₹1,657.70
52 Week Range	₹802.00 - ₹1,309.90	₹1,345.00 - ₹2,664.00
% from 52W High	-18.28%	-37.77%
All-Time High	₹1,309.90 (Nov 04, 2024)	₹2,664.00 (Sep 16, 2024)
% from All-Time High	-18.28%	-37.77%
Growth Metrics
Quarterly Revenue Growth	0.10%	-0.06%
Quarterly Earnings Growth	-0.79%	-0.26%
Financial Health
Profit Margin (TTM) i	0.06%	0.30%
Operating Margin (TTM) i	0.10%	0.21%
Return on Equity (TTM) i	0.13%	0.21%
Debt to Equity (MRQ) i	43.78	0.16
Cash & Liquidity
Book Value per Share (MRQ)	₹395.41	₹173.28
Cash per Share (MRQ)	₹68.67	₹30.36
Operating Cash Flow (TTM) i	₹8.86B	₹2.98B
Levered Free Cash Flow (TTM) i	₹8.39B	₹3.72B
Dividends
Last 12-Month Dividend Yield i	0.85%	0.44%
Last 12-Month Dividend i	₹10.00	₹8.75

Valuation & Enterprise Metrics Analysis: Jubilant Pharmova vs Concord Biotech

Metric	JUBLPHARMA	CONCORDBIO
Price Ratios
P/E Ratio (TTM) i	36.96	49.11
Forward P/E i	22.51	33.20
PEG Ratio i	-0.47	-1.88
Price to Sales (TTM) i	2.29	14.69
Price to Book (MRQ) i	2.71	9.63
Market Capitalization
Market Capitalization i	₹169.87B	₹173.68B
Enterprise Value i	₹185.97B	₹171.48B
Enterprise Value Metrics
Enterprise to Revenue i	2.51	14.43
Enterprise to EBITDA i	15.13	35.54
Risk & Other Metrics
Beta i	0.69	0.95
Book Value per Share (MRQ) i	₹395.41	₹173.28

Financial Statements Comparison: Jubilant Pharmova vs Concord Biotech

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)	JUBLPHARMA	CONCORDBIO
Revenue/Sales i	₹19.16B	₹2.04B
Cost of Goods Sold i	₹6.26B	₹451.04M
Gross Profit i	₹12.90B	₹1.59B
Research & Development i	N/A	N/A
Operating Income (EBIT) i	₹2.50B	₹436.22M
EBITDA i	₹3.57B	₹765.67M
Pre-Tax Income i	₹2.06B	₹587.32M
Income Tax i	₹547.00M	₹146.74M
Net Income (Profit) i	₹1.51B	₹440.58M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)	JUBLPHARMA	CONCORDBIO
Cash & Equivalents i	₹10.88B	₹9.05M
Total Current Assets i	₹35.77B	₹11.35B
Total Current Liabilities i	₹21.65B	₹1.84B
Long-Term Debt i	₹23.89B	₹6.30M
Total Shareholders Equity i	₹62.39B	₹18.13B
Retained Earnings i	N/A	N/A
Property, Plant & Equipment i	₹24.54B	₹7.94B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)	JUBLPHARMA	CONCORDBIO
Operating Cash Flow i	N/A	N/A
Capital Expenditures i	N/A	N/A
Free Cash Flow i	N/A	N/A
Debt Repayment i	N/A	N/A
Common Stock Repurchase i	N/A	N/A

Short Interest & Institutional Ownership Analysis

Metric	JUBLPHARMA	CONCORDBIO
Shares Short i	N/A	N/A
Short Ratio i	N/A	N/A
Short % of Float i	N/A	N/A
Average Daily Volume (10 Day) i	130,425	114,810
Average Daily Volume (90 Day) i	277,029	117,481
Shares Outstanding i	158.40M	104.62M
Float Shares i	63.48M	26.36M
% Held by Insiders i	0.61%	0.75%
% Held by Institutions i	0.22%	0.14%

Dividend Analysis & Yield Comparison: Jubilant Pharmova vs Concord Biotech

Metric	JUBLPHARMA	CONCORDBIO
Last 12-Month Dividend i	₹10.00	₹8.75
Last 12-Month Dividend Yield i	0.85%	0.44%
3-Year Avg Annual Dividend i	₹6.67	₹2.92
3-Year Avg Dividend Yield i	0.89%	0.56%
3-Year Total Dividends i	₹20.00	₹8.75
Ex-Dividend Date	Jul 25, 2025	Jun 21, 2024